For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...

Although the clinical data supporting the combination of teclistamab and daratumumab are exceptional, Luciano Costa, MD, PhD, Director of the Multiple Myeloma Research and Treatment Program at the ...

Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial. This is an ASCO Meeting ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Luciano Costa, MD, PhD, discusses the considerations for managing infection risk with bispecific antibodies in multiple myeloma. Luciano Costa, MD, PhD, Director of the Multiple Myeloma Research and ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...

Rates infection related cancer have increased among solid organ transplant recipients, CDC reports a five-fold rise in Kaposi sarcoma virus transmission.

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...